TCM
BHVN

Tang Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Tang Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-280,000
Closed -$42.3M – 112
2022
Q3 		$42.3M Hold
280,000
– – 5.19% 2
2022
Q2 		$40.8M Buy
+280,000
New +$35.8M 6.19% 4
2020
Q4 		– Sell
-599,091
Closed -$38.9M – 24
2020
Q3 		$38.9M Sell
599,091
-381,370
-39% -$25M 7.05% 4
2020
Q2 		$71.7M Buy
+980,461
New +$52.2M 6.97% 2

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Tang Capital Management's BHVN Position: Q4 2022 in Review

Tang Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 280,000 shares — an estimated $42.3M sold.

Tang Capital Management first reported a position in BHVN in Q2 2020 and held it in 4 quarters. The position peaked at $71.7M in Q2 2020. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Tang Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Tang Capital Management sold 280,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $42.3M.
  • Tang Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 4 quarters.
  • Tang Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $71.7M in Q2 2020.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Tang Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.